Homie Razavi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3668642/publications.pdf

Version: 2024-02-01

89 papers	23,908 citations	87888 38 h-index	49909 87 g-index
90 all docs	90 docs citations	90 times ranked	35534 citing authors

#	Article	IF	Citations
1	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2224-2260.	13.7	9,397
2	The State of US Health, 1990-2010. JAMA - Journal of the American Medical Association, 2013, 310, 591.	7.4	2,070
3	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
4	Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 2014, 61, S45-S57.	3.7	1,560
5	Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018, 67, 123-133.	7.3	1,474
6	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. The Lancet Gastroenterology and Hepatology, 2018, 3, 383-403.	8.1	1,241
7	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
8	Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 797-808.	9.1	542
9	Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology, 2013, 57, 2164-2170.	7.3	397
10	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 2014, 21, 34-59.	2.0	372
11	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2019, 4, 135-184.	8.1	370
12	Hepatitis C virus infection. Nature Reviews Disease Primers, 2017, 3, 17006.	30.5	354
13	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
14	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 325-336.	8.1	208
15	The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Seminars in Liver Disease, 2018, 38, 181-192.	3.6	185
16	Global, regional, and countryâ€level estimates of hepatitis C infection among people who have recently injected drugs. Addiction, 2019, 114, 150-166.	3.3	178
17	Global timing of hepatitis C virus elimination in highâ€income countries. Liver International, 2020, 40, 522-529.	3.9	147
18	Burden of Disease and Cost of Chronic Hepatitis C Virus Infection in Canada. Canadian Journal of Gastroenterology and Hepatology, 2014, 28, 243-250.	1.9	131

#	Article	IF	Citations
19	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	3.7	114
20	Historical epidemiology of hepatitis C virus (<scp>HCV</scp>) in select countries â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 4-20.	2.0	109
21	Modelling NAFLD disease burden in four Asian regionsâ€”2019â€“2030. Alimentary Pharmacology and Therapeutics, 2020, 51, 801-811.	3.7	92
22	Global Epidemiology of Viral Hepatitis. Gastroenterology Clinics of North America, 2020, 49, 179-189.	2.2	89
23	The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab Journal of Gastroenterology, 2014, 15, 45-52.	0.9	88
24	Progress towards hepatitis C virus elimination in highâ€income countries: An updated analysis. Liver International, 2021, 41, 456-463.	3.9	81
25	Global prevalence of hepatitis C virus in children in 2018: a modelling study. The Lancet Gastroenterology and Hepatology, 2020, 5, 374-392.	8.1	80
26	Nonalcoholic fatty liver disease burden â€“ Saudi Arabia and United Arab Emirates, 2017â€“2030. Saudi Journal of Gastroenterology, 2018, 24, 211.	1.1	77
27	Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. The Lancet Gastroenterology and Hepatology, 2019, 4, 794-804.	8.1	68
28	Nonalcoholic fatty liver disease burden: Australia, 2019â€“2030. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1628-1635.	2.8	68
29	Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis <scp>C</scp>â€related liver disease and costs in <scp>A</scp>ustralia. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1-9.	2.8	67
30	Global genotype distribution of hepatitis C viral infection among people who inject drugs. Journal of Hepatology, 2016, 65, 1094-1103.	3.7	63
31	Strategies to manage hepatitis C virus infection disease burden â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 42-65.	2.0	62
32	The present and future disease burden of hepatitis C virus infections with today's treatment paradigm â€“ volume 3. Journal of Viral Hepatitis, 2015, 22, 21-41.	2.0	61
33	Chronic hepatitis C burden and care cascade in Australia in the era of interferonâ€based treatment. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 229-236.	2.8	61
34	Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. Journal of Medical Economics, 2012, 15, 887-896.	2.1	60
35	Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study. Journal of Viral Hepatitis, 2019, 26, 83-92.	2.0	58
36	The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination. Clinical Infectious Diseases, 2019, 69, 2218-2227.	5.8	52

#	Article	IF	Citations
37	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 2021, 10, .	6.0	50
38	Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepatitis Monthly, 2016, 16, e37234.	0.2	44
39	Burden of nonalcoholic fatty liver disease in Canada, 2019â€“2030: a modelling study. CMAJ Open, 2020, 8, E429-E436.	2.4	42
40	Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach. Brazilian Journal of Infectious Diseases, 2019, 23, 182-190.	0.6	37
41	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver International, 2020, 40, 1545-1555.	3.9	37
42	The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up. Health Policy and Planning, 2018, 33, 528-538.	2.7	34
43	The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandinavian Journal of Gastroenterology, 2015, 50, 233-244.	1.5	33
44	Forecasting Hepatitis C liver disease burden on realâ€life data. Does the hidden iceberg matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	3.9	33
45	The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.	2.0	28
46	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE, 2015, 10, e0125214.	2.5	25
47	EliminaciÃ³n de la hepatitis C en EspaÃ±a: adaptaciÃ³n de un modelo matemÃ¡tico de salud pÃºblica partiendo del plan estratÃ©gico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Medicina ClÃnica, 2017, 148, 277-282.	0.6	24
48	HCV elimination among people who inject drugs. Modelling pre- and postâ€“WHO elimination era. PLoS ONE, 2018, 13, e0202109.	2.5	24
49	Securing sustainable funding for viral hepatitis elimination plans. Liver International, 2020, 40, 260-270.	3.9	24
50	Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?. The Lancet Gastroenterology and Hepatology, 2020, 5, 948-953.	8.1	24
51	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. The Lancet Gastroenterology and Hepatology, 2021, 6, 169-184.	8.1	24
52	Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission â€“ Authors' reply. The Lancet Gastroenterology and Hepatology, 2018, 3, 599.	8.1	21
53	The hepatitis B epidemic and the urgent need for cure preparedness. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 517-518.	17.8	20
54	Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi Journal of Gastroenterology, 2016, 22, 269.	1.1	19

#	Article	IF	Citations
55	Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Network Open, 2020, 3, e204192.	5.9	17
56	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	4.0	16
57	Disease burden of chronic hepatitis C in Brazil. Brazilian Journal of Infectious Diseases, 2015, 19, 363-368.	0.6	15
58	HCV disease burden and population segments in Switzerland. Liver International, 2022, 42, 330-339.	3.9	14
59	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. Journal of Viral Hepatitis, 2022, 29, 536-542.	2.0	14
60	Estimating <scp>HCV</scp> disease burden â€“ volume 3 (editorial). Journal of Viral Hepatitis, 2015, 22, 1-3.	2.0	13
61	Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. World Journal of Gastroenterology, 2019, 25, 1327-1340.	3.3	13
62	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PLoS ONE, 2018, 13, e0209374.	2.5	12
63	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. PLoS ONE, 2020, 15, e0235715.	2.5	12
64	Nonalcoholic fatty liver disease burden â€“ Switzerland 2018â€“2030. Swiss Medical Weekly, 2019, 149, w20152.	1.6	12
65	Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Medical Weekly, 2017, 147, w14543.	1.6	12
66	Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 466-472.	2.8	10
67	Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVIDâ€19. Liver International, 2021, 41, 2024-2031.	3.9	9
68	Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model â€" Tashkent, Uzbekistan, December 6, 2019â€“March 15, 2020. Morbidity and Mortality Weekly Report, 2020, 69, 1161-1165.	15.1	9
69	Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Medical Weekly, 2019, 149, w20026.	1.6	9
70	Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models. PLoS ONE, 2020, 15, e0237525.	2.5	8
71	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Medical Weekly, 2015, 145, w14221.	1.6	8
72	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. Swiss Medical Weekly, 2019, 149, w14694.	1.6	7

#	Article	IF	Citations
73	Opportunistic coâ€screening for <scp>HCV</scp> and <scp>COVID</scp>â€19â€related services: A creative response with a need for thoughtful reflection. Liver International, 2022, 42, 960-962.	3.9	7
74	Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System. Medicina ClÃnica (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	6
75	Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study. Acta Clinica Belgica, 2018, 73, 50-53.	1.2	6
76	Disease burden of hepatitis C in the Austrian state of Tyrol â€“ Epidemiological data and model analysis to achieve elimination by 2030. PLoS ONE, 2018, 13, e0200750.	2.5	6
77	Response to letter to the editor: Strategies to reduce <scp>HCV</scp> disease burden and <scp>HCV</scp> transmission need different models, as what works for endâ€stage liver disease may not work for <scp>HCV</scp> prevalence: a comment on the results presented in <scp>JVH</scp> Special Issue. Journal of Viral Hepatitis, 2014, 21, e169-70.	2.0	4
78	HCVâ€infected patients need access now to new directâ€acting antiviral agents to avert liverâ€related deaths. Medical Journal of Australia, 2015, 202, 479-479.	1.7	4
79	Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatology International, 2017, 11, 509-516.	4.2	4
80	The costâ€effectiveness of hepatitis C virus elimination in lowâ€and middleâ€income countries. Journal of Viral Hepatitis, 2021, 28, 445-445.	2.0	4
81	Chronic hepatitis C in the Czech Republic: Forecasting the disease burden. Central European Journal of Public Health, 2019, 27, 93-98.	1.1	4
82	Hepatitis C virus infection in Argentina: Burden of chronic disease. World Journal of Hepatology, 2016, 8, 649.	2.0	4
83	The Payer License Agreement, or â€œNetflix model,â€•for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition. Liver International, 2022, 42, 1503-1516.	3.9	4
84	Making the case for looking beyond <scp>WHO</scp> estimates for the global burden of hepatitis C and B. Journal of Viral Hepatitis, 2016, 23, 576-576.	2.0	3
85	A micro-elimination approach to addressing hepatitis C in Turkey. BMC Health Services Research, 2020, 20, 249.	2.2	3
86	A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea. PLoS ONE, 2020, 15, e0232186.	2.5	3
87	Polaris Observatoryâ€”supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis. Antiviral Therapy, 2022, 27, 135965352210831.	1.0	3
88	Response to Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver International, 2020, 40, 1507-1507.	3.9	0
89	Editorial: increasing burden of nonalcoholic fatty liver diseaseâ€”a call to action. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1430-1432.	3.7	0